ABSCI CORP Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
ABSCI CORP (ABSI) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $69.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-03-24
- ABSCI CORP proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $4.30M, a 90.44% decline year-over-year.
- ABSCI CORP proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $39.00M, a 9.30% decline year-over-year.
- ABSCI CORP proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-06-30 was $26.00M, a 52.29% decline year-over-year.
- ABSCI CORP proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-03-31 was $25.00M, a 27.75% decline year-over-year.
- ABSCI CORP proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $69.50M, a 60.76% decline from fiscal 2024.
- ABSCI CORP proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $177.10M, a 26.70% decline from fiscal 2023.
- ABSCI CORP proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $241.60M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2025-12-31 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $43.30M derived: sum of 2 quarters · filed 2026-03-24 | $69.30M derived: sum of 3 quarters · filed 2026-03-24 | $69.50M 10-K · filed 2026-03-24 |
| 2025-09-30 | $39.00M 10-Q · filed 2025-11-12 | $65.00M derived: sum of 2 quarters · filed 2025-11-12 | $65.20M 10-Q · filed 2025-11-12 | $135.00M derived: sum of 4 quarters · filed 2026-03-24 |
| 2025-06-30 | $26.00M 10-Q · filed 2025-08-12 | $51.00M 10-Q · filed 2025-08-12 | $96.00M derived: sum of 3 quarters · filed 2026-03-24 | $139.00M derived: sum of 4 quarters · filed 2026-03-24 |
| 2025-03-31 | $25.00M 10-Q · filed 2025-05-13 | $70.00M derived: sum of 2 quarters · filed 2026-03-24 | $113.00M derived: sum of 3 quarters · filed 2026-03-24 | $167.50M derived: sum of 4 quarters · filed 2026-03-24 |
| 2024-12-31 | $45.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $88.00M derived: sum of 2 quarters · filed 2026-03-24 | $142.50M derived: sum of 3 quarters · filed 2026-03-24 | $177.10M 10-K · filed 2026-03-24 |
| 2024-09-30 | $43.00M 10-Q · filed 2025-11-12 | $97.50M derived: sum of 2 quarters · filed 2025-11-12 | $132.10M 10-Q · filed 2025-11-12 | $183.80M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $54.50M 10-Q · filed 2025-08-12 | $89.10M 10-Q · filed 2025-08-12 | $140.80M derived: sum of 3 quarters · filed 2025-08-12 | $194.80M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $34.60M 10-Q · filed 2025-05-13 | $86.30M derived: sum of 2 quarters · filed 2025-05-13 | $140.30M derived: sum of 3 quarters · filed 2025-05-13 | $234.20M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $51.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $105.70M derived: sum of 2 quarters · filed 2025-03-18 | $199.60M derived: sum of 3 quarters · filed 2025-03-18 | $241.60M 10-K · filed 2025-03-18 |
| 2023-09-30 | $54.00M 10-Q · filed 2024-11-12 | $147.90M derived: sum of 2 quarters · filed 2024-11-12 | $189.90M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $93.90M 10-Q · filed 2024-08-14 | $135.90M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $42.00M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |